New Colon Cancer Biomarkers May Guide Development of Personalized Treatment
Researchers are first to demonstrate the role of a circular RNA, ciRS-7, in colon cancer
Researchers at Baylor Scott & White Research Institute identified a new genetic biomarker for colon cancer that may lead to development of more targeted treatment of the disease. The study, which appeared in a recent issue of Clinical Cancer Research, was the first to demonstrate the role of a novel class of RNA, circular RNA ciRS-7, in colon cancer.
Circular RNAs, a recently discovered type of non-coding RNA, are gene regulators emerging as a key player in the development of cancer in several studies. For this study, researchers evaluated the expression levels of ciRS-7 in patients with colon cancer and healthy subjects to explore its clinical significance in the disease.
Findings showed an increased presence of ciRS-7 in colon cancer patient tissues. High levels of ciRS-7 promoted rapid cancer cell growth and appeared to be a predictor for poor survival in patients with colon cancer.
The results suggest ciRS-7 may one day help predict patient prognosis and guide treatment decisions for colon cancer, the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the U.S.
"This study is important for the way we treat colon cancer, because ciRS-7 controls the expression of many genes," said Ajay Goel, Ph.D., director of gastrointestinal research and translational genomics and oncology at Baylor Scott & White Research Institute and co-author of the study. "Since cancer therapies aimed at targeting a single gene have not been very effective, targeting a circular RNA such as ciRS-7 might be a more promising and attractive option as it regulates the expression of several cancer causing genes. Identifying key treatment targets helps with the development of very specific, personalized anti-cancer interventions that may save more lives in the future."
About Baylor Scott & White Health
Formed from the 2013 merger between Baylor Health Care System and Scott & White Healthcare, the system referred to as Baylor Scott & White Health is the largest not-for-profit health care system in the state of Texas. With total assets of $10.8 billion* and serving a population larger than the state of Georgia, Baylor Scott & White Health has the vision and resources to provide its patients continued quality care while creating a model system for a dramatically changing health care environment. The system now includes 48 hospitals, more than 1,000 access points, 5,500 active physicians, and 44,000 employees, plus the Scott & White Health Plan, Baylor Scott & White Research Institute and Baylor Scott & White Quality Alliance — a network of clinical providers and facilities focused on improving quality, managing the health of patient populations, and reducing the overall cost of care. For more information visit:
* based on unaudited 2014 fiscal year statements
# # #← View All ↑ Back to Top